Stay updated with breaking news from Hocul. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reaffirmed their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a research note published on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 target price on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on the stock. StockNews.com cut shares of Ocular Therapeutix […] ....
JMP Securities restated their market outperform rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a $24.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a buy […] ....
Ocular Therapeutix (NASDAQ: OCUL) has recently received a number of price target changes and ratings updates: 3/10/2024 – Ocular Therapeutix was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating. 3/2/2024 – Ocular Therapeutix was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 2/26/2024 – Ocular […] ....
Paradigm Capital Management Inc. NY increased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 100.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,000 shares of the biopharmaceutical company’s stock after acquiring an additional 40,000 shares […] ....
Paradigm Capital Management Inc. NY grew its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 100.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 80,000 shares of the biopharmaceutical company’s stock after buying an additional 40,000 shares during the quarter. […] ....